Conatus Pharmaceuticals Reports 2015 Financial Results and Program Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Conatus Pharmaceuticals (CNAT) Tops Q4 EPS by 7c
March 9, 2016 4:17 PM ESTConatus Pharmaceuticals (NASDAQ: CNAT) reported Q4 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Conatus Pharmaceuticals (CNAT) click here.
... More